Evidence map›Paper›PMID 40320334›Full record

Observational studyAnnals of the rheumatic diseases2025

A cross-sectional observational study of patients with sicca with salivary autoantibodies defines a potential new phenotype of Sjögren's disease.

Martha Tsaliki, Joshua Cavett, Biji T Kurien, Christina Bruxvoort, Valerie M Lewis, John A Ice, Devavrat Dave, Sina Khosravani, Kiely Grundahl, Christopher J Lessard and 5 more

Abstract readObservational Study
In one paragraph

Observational study in Annals of the rheumatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Martha TsalikiArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Oklahoma City US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma.
Joshua CavettArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Oklahoma City US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma.
Biji T KurienArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Oklahoma City US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma.
Christina BruxvoortArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Oklahoma City US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma.
Valerie M LewisArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Oklahoma City US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma.
John A IceArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Oklahoma City US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma.
Devavrat DaveArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Departments of Medicine and Pathology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Sina KhosravaniArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Kiely GrundahlArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Genes and Human Diseases Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Christopher J LessardDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; Genes and Human Diseases Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Astrid RasmussenGenes and Human Diseases Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Kathy L SivilsArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Amy Darise FarrisArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Kristi A KoelschArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Robert Hal ScofieldArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Oklahoma City US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma; Departments of Medicine and Pathology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. Electronic address: hal-scofield@omrf.ouhsc.edu.

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Janis E Campbell · 2013 to 2026
$68.2M
Pathogenic B Cells in Sjogren's SyndromeP50AR060804 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI SIVILS, KATHY L. · 2011 to 2015
$7.9M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2007 to 2017
$6.7M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
Sjogren's Syndrome Pathogenic AutoantibodiesR01DE028001 · NIDCR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI SCOFIELD, ROBERT HAL · 2019 to 2023
$1.7M
Saliva Anti-SSA/Ro and Anti-SSB/La for Early Detection of Sjögren’s and SICCA SyndromesR21DE033901 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S., SCOFIELD, ROBERT HAL · 2024 to 2025
$465k
NIAID NIH HHS U19 AI082714NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P50 AR060804NIDCR NIH HHS R01 DE028001NIDCR NIH HHS R21 DE033901NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

objectivesDiagnosis of Sjögren's disease (SjD) consists of clinical examinations that include invasive studies such as lower lip biopsies and blood collection to identify presence of serum autoantibodies. Salivary glands of patients with SjD are sites where antibody-secreting cells accumulate and secrete immunoglobulins. Many patients with dry manifestations who do not meet classification criteria are grouped as non-Sjögren's sicca (NSS) and are heavily understudied. We undertook this cross-sectional observational study to investigate the role of salivary autoantibodies as a diagnostic tool and determine presence of salivary autoantibodies in patients with NSS.

methodsIn this cross-sectional observational study, we screened whole unstimulated saliva from 446 subjects by direct enzyme-linked immunosorbent assays and capillary western blotting for anti-Ro60, anti-La, and rheumatoid factor (immunoglobulin (Ig)G and IgA) antibodies. All subjects were classified following the ACR/EULAR classification at the Oklahoma Medical Research Foundation Sjögren's Research Clinic.

resultsPatients with SjD were significantly more likely to have salivary antibodies compared with those with NSS and healthy control subjects. In this cohort, there were 88 subjects with NSS with seronegative profiles who had detectable salivary autoantibodies and objective measures of dryness.

conclusionsOf these 88 subjects with NSS, we identified 75 subjects that had positive objective examinations of dryness and could belong to an early-onset SjD group. Alternatively, these 75 subjects with NSS could belong to a distinct phenotype of SjD that will remain seronegative while being saliva positive for anti-Ro60. These data showed a relationship between ocular and oral dryness and the presence of salivary anti-Ro60 antibodies in subjects with NSS.

Indexed as

AutoantibodiesSalivaSjogren's SyndromeAdultAgedAntibodies, AntinuclearCross-Sectional StudiesFemaleHumansImmunoglobulin AImmunoglobulin GMaleMiddle AgedPhenotypeRheumatoid FactorRibonucleoproteinsAntibodies, AntinuclearAutoantibodiesImmunoglobulin AImmunoglobulin GRheumatoid FactorRibonucleoproteinsSS-A antibodies

Identifiers

PMID40320334
PMCPMC12642395

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.